Menu Schließen
Improving Quality of Life of
Peritoneal Dialysis Patients

News & Press Releases

Welcome Elizabeth & Maxim

Welcome 🤝 Elizabeth Lensmith and Maxim Voropaiev! 🎉 The Opterion team is happy ✨ to have you on board. Elizabeth supports us as Scientific/Technical Project Support Associate. She holds a master’s degree (MSc) in Pharmatechnology and Drug Manufacturing. With her background in drug analysis, she is a great addition to our team. 💎 Opterion’s new Chief Medical Officer is Maxim Voropaiev. He holds a Medical Doctor (MD) 🩺 degree and a master’s degree (MAS) in statistics.

Read More »

Changes to the Board of Directors

The Board and the Management Team of Opterion Health AG thanks🙏 Stefan Wohlfeil for his support and his outstanding contribution to the continuing success of the company. Stefan Wohlfeil has decided to retire and step down as a member of the Board of Directors, but remains a partner and shareholder. At the Opterion Health AG extraordinary General Meeting, held on September 19, 2023, the shareholders elected Jan-Anders Karlsson and Robert Leitz as new members of

Read More »

Opterion Health closes financing round and announces changes to its Board of Directors

Muttenz, Switzerland, 20 September 2023 – Opterion Health AG, a Swiss-based life sciences company developing the first major innovation in peritoneal dialysis (PD) for two decades, today announced the successful completion of a CHF 6.5m financing round. The proceeds will be used to complete ongoing preclinical activities and prepare for the start of Phase I studies. Separately, Stefan Wohlfeil has decided to retire and step down as a member of the Board of Directors. At the Extraordinary General Meeting (EGM) on 19 September 2023, shareholders elected Jan-Anders Karlsson and Robert Leitz as new members of the Board of Directors.

Read More »

Annual General Meeting

At this year’s Annual General Meeting, the Opterion Health shareholders voted in favour of all proposed topics. Also the members of the Board of Directors were re-elected – congratulations to David Ebsworth, Ricardo Cordero and Stefan Wohlfeil. The business and scientific updates presented by the CEO Peter Reinemer and Guido Grentzmann (Founder & CSO) highlighted that the company is well on track with the development of OPT 100, Opterion Health’s lead development product – a

Read More »

Opterion Health at ERA Congress

Meet us at the 60th European Renal Association (ERA) Congress taking place in Milan, Italy from June, 15 – 18, 2023. Guido Grentzmann is attending this largest annual Nephrology Congress in Europe, which focuses on key learning features both in the clinical field as well as the scientific and latest innovations. Are you interested in learning more about Opterion Health’s novel peritoneal dialysis (PD) solution, aiming to minimize the side effects of PD and which

Read More »

The Opterion Health AG team welcomes Marc Willuhn!

Marc has recently joined as Head CMC and provides scientific guidance, projectmanagement support and regulatory expertise in the field of chemistry, manufacturing and controls (CMC). He has more than 20 years of experience in drug development for global markets, and held senior leadership roles at Fresenius Kabi and Baxter Healthcare. Marc is an excellent addition to our team and will define, drive and oversee Opterion Health AG’s pharmaceutical development and manufacturing activities for preclinical and

Read More »

Opterion Health appoints Peter Reinemer as CEO

Muttenz, Switzerland, 18 January 2023 – Opterion Health AG, a Swiss-based life sciences company developing the first major innovation in peritoneal dialysis (PD) for two decades, today announced that Peter Reinemer has been appointed Chief Executive Officer. Currently Chief Technology Officer, Peter will assume the role of CEO in addition to his current position, with effect from 1st February 2023, replacing Björn Englund, who is leaving the company to take a leadership role at a major player in the field of dialysis.

Read More »

Meet the team – Ulrike

Name: Ulrike Grimm

Role: Head of Project Management
Ulrike joined Opterion Health’s management team as Head of Project Management in June 2020. She has held several leadership positions in big pharma companies, gaining extensive project management experience.

Read More »

Commitment to Quality

At Opterion Health, we aim to improve the quality of life for patients, their caregivers and loved ones as well as attempt to increase the survival rates of people who suffer from chronic kidney disease. Quality is important to us and everyone at Opterion Health is committed to maintain a culture of quality and mitigate risk through appropriate systems and processes. Learn more about Opterion Health and the novel solution for peritoneal dialysis (PD) we

Read More »

Annual General Meeting (AGM)

Opterion Health held its first Annual General Meeting at its new headquarters at The 5th Floor, in Muttenz, Baselland. The hybrid meeting was well attended by our shareholders – in person or online. All agenda items were unanimously approved by all votes represented. David Ebsworth, Chairman, thanked the two exiting Members of the Board of Directors (BoD), Guido Grentzmann and Andreas Schmidt, for their substantial and valuable contribution over the past years. On behalf of the

Read More »

Meet the team – Guido

Name: Guido Grentzmann

Role: Founder / CSO
Guido Grentzmann founded Opterion in 2012 with the aim to develop a new solution for peritoneal dialysis that will reduce side effects. More than 25 years ago and after he spent some time in academic research in bacterial and viral translational regulation, Guido went into pharmaceutical R&D, working on therapeutical targets, biomarkers and signal pathways in different therapeutic areas, in different roles.

Read More »

Opterion Health AG office inauguration in Muttenz

Yesterday, the new Opterion Health AG office in Muttenz, Baselland, was officially inaugurated and the entire team was overwhelmed to welcome so many guests, and celebrate together with our partner HEMEX and The 5th Floor. Ricardo Cordero, Vice Chairman, and David Ebsworth, Chairman of Opterion, welcomed the guests; Englund, Björn, Opterion’s CEO shared insights into the PeritonealDialysis market and company’s vision. Dr. Susanne H. Hoischen, Nephrologist and Founder & Managing Partner of Sanecum Group, highlighted

Read More »

Opterion Health strengthens its Management Team

Muttenz, Switzerland, 16 September 2021 – Opterion Health AG, a nephrology company focused on innovation in Peritoneal Dialysis (PD), today announced a significant strengthening of its management team, including the appointments of Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been appointed Head of Quality and Ulrike Grimm Head of Project Management. Andreas Schmidt, whom Daniel Lustenberger succeeds as CFO, will continue to support Opterion Health as a partner.

Read More »

Björn Englund’s first 100 days as Opterion Health CEO

15 July 2021 – It’s been about 100 days since Englund, Björn joined Opterion Health AG as CEO. With his broad background in the dialysis business, how has he experienced his start with Opterion? “The last 100 days have been awesome! Our drive for innovation at Opterion and the novel solution for peritoneal dialysis (PD) we are developing will be a real game changer in dialysis and, more importantly, will improve patients’ quality of life once

Read More »

Opterion Health moved to Muttenz

3 June 2021 – Hello The 5th Floor – hello Muttenz, Baselland! Opterion Health AG has just moved into its new offices and is excited to become part of the innovative life sciences ecosystem around Basel. The new offices, next to the recently launched inQbator – a startup accelerator created through a partnership between BLKB, HEMEX and Launchpad – and other innovative companies are inspiring and will help us advance our goal to bring innovation

Read More »

Opterion Health AG appoints Björn Englund as CEO

25 March 2021 – Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) in the last two decades, today announced the appointment of Björn Englund as CEO. He will take over this role in April 2021, succeeding Guido Grentzmann, the founder and CSO of Opterion, who will focus his activities on the scientific development of the company and the preparation of the start of Phase I.

Read More »

Opterion Health presented at ISPD Conference

9 March 2021 – Guido Grentzmann, CEO and CSO of Opterion Health AG, shared insights on our new osmotic driver for Peritoneal Dialysis (PD) at the recent virtual ISPD (International Society for Peritoneal Dialysis)-EuroPD Joint Conference: Common PD fluids use glucose as osmotic driver (ODR) at concentrations between 1% and 5%. The high glucose concentration of conventional PD fluids leads to high initial osmotic pressure. The back-diffusion of glucose, from the dialysate into the patient’s bloodstream, presents a

Read More »

HEMEX Article: Bringing Innovation to Dialysis Care and foster Home Dialysis

17 February 2021 – Our portfolio company Opterion Health AG seeks to enhance the quality of life for patients with end-stage renal disease (ESRD) and their loved ones, and to increase survival rates of ESRD patients. They launched their new website at the beginning of the year and have very exciting plans for 2021! Chronic kidney disease is the progressive loss of kidney function. When it reaches an advanced state, end-stage renal disease (ESRD) appears. During

Read More »

Opterion at the virtual ISPD conference

12 February 2021 – Amelie Tsoutsoulopoulos and Guido Grentzmann from Opterion Health AG are participating at the virtual ISPD (International Society for Peritoneal Dialysis) – EuroPD Joint Conference. Meet the Opterion team at the oral presentation ‘Osmotically active composition for peritoneal Dialysis’, taking place Monday, 1st March 2021, from 18:15 – 19:45 (CET) / 17:15 – 18:45 (UTC) / 12:15 – 13:45 (ET) in the ‘Free Communications – Basic Science’ session.

Read More »

Improving Quality of Life of Dialysis patients

6 February 2021 – “About 40% of dialysis incidence is due to diabetes. Further, in times of a pandemic, as we are currently experiencing, an increasing number of patients are reluctant to visit a clinic or a hospital,” says Guido Grentzmann, the founder and CEO/CSO of Opterion Health AG. “Therefore, a physiological glucose or glucose-free peritoneal dialysis (PD) solution, which Opterion has in pre-clinical development, is a much-needed innovation, not only for diabetic dialysis patients, but

Read More »

Moving to the Basel area

26 January 2021 – The entire Opterion Health AG team is excited to move to ‘The 5th Floor’ in Muttenz, Basel-Landschaft, and benefit from the innovative life sciences ecosystem around Basel. A big thank you to the ‘Basel Area Business & Innovation’ team for their excellent support.  

Read More »

Opterion Health AG moving to Muttenz

22 January 2021 – Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from the local life sciences ecosystem. Following a significantly oversubscribed bridge financing round, Opterion was able to raise a total of 8.4 million euros for its innovative peritoneal dialysis solution. Opterion Health AG has announced its intention to vacate its current headquarters in Sarnen in the canton of Obwalden and move to

Read More »

Opterion successfully secures EUR 8.4m Bridge Financing Round

19 January 2021 – Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) in the last two decades, today announced the successful agreement of a EUR 8.4m Bridge Financing Round. This amount was exclusively raised from a limited number of professional private and institutional investors based in Switzerland and Germany. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I.

Read More »

Robert Leitz

Board Member
Robert Leitz has 20 years of experience at renowned financial institutions and is the Managing Director of iolite Capital, a private investment firm based in Pfäffikon SZ, Switzerland. Before iolite, he held positions at Glencore (the world’s largest commodity trader) and various financial institutions, including TPG Credit (a hedge fund), Goldman Sachs’ European Special Situations Group, and KPMG Corporate Restructuring. Robert graduated from the University of St. Gallen (HSG), Switzerland, with an MSc. in Business Administration and Economics, and wrote his master’s thesis under the guidance of Prof. Eli Noam at Columbia University, New York. Robert is a member of the Entrepreneurs’ Organization (EO) and is Finance Chair for the Zurich chapter.

Maxim Voropaiev

Chief Medical Officer
Maxim Voropaiev joined Opterion in November 2023 as Chief Medical Officer (CMO). Maxim has 20 years of experience in the pharmaceutical industry in global, strategic roles with increasing responsibilities in clinical development, medical affairs, and statistics. Having worked in multiple therapeutic areas (oncology, kidney disease, gastroenterology, autoimmune/inflammatory diseases, neurological disease and respiratory tract) at the headquarters of companies like Novartis, Vifor Pharma (now CSL) and Bayer, Maxim has built a unique set of skills geared towards the excellence in clinical studies design and execution. Maxim holds a medical doctor (MD) degree and a master degree (MAS) in statistics.

Marc Willuhn

Head of CMC
Marc Willuhn joined Opterion in January 2023 as Head of CMC. Marc has more than 20 years of experience in drug development for global markets. He has an outstanding track record in pharmaceutical product development, resulting in several approved products. Marc held senior leadership roles at Fresenius Kabi and Baxter Healthcare before founding his own company in 2018, providing technical and strategic consulting services to life sciences companies. Marc holds a master’s degree in chemistry (Gerhard-Mercator-University Duisburg, Germany) and a PhD in organic chemistry from the Max-Planck-Institute for Coal Research in Mülheim/Ruhr, Germany. He completed postdoctoral studies at the Faculté de Pharmacie in Paris, France, and also holds an MBA.

Ulrike Grimm

Chief of Staff & Head of Project Management

Opterion Health engaged Ulrike Grimm in June 2020 to establish project excellence for its development program.

Ulrike started her career as a sales representative for Sanol Pharma and joined Merck KGaA in 1997, where she held roles of increasing responsibility starting as team leader for R&D projects and continuing as product leader for Merck’s second commercial oncology drug.

From 2007 to 2010 she was the Vice President of Project and Portfolio Management at Fresenius Biotech. Ulrike joined Vifor Pharma in 2010 and served as the Vice President for Project and Alliance Management as well as Clinical Operations during the next eight years. In 2019 Ulrike started her own consulting company Pro2S AG.

Peter Reinemer

Chief Executive Officer

Peter Reinemer, PhD, MBA, has been appointed as Chief Executive Officer (CEO) of the company as of February 2023. He joined Opterion in July 2021 as Chief Technology Officer (CTO) and will assume this position in addition to his new role for the time being.

Peter has more than 30 years of experience in the pharmaceutical and biotechnology industries, and began his career at Bayer Pharma, where he spent over 10 years in discovery research in Germany and Japan. He subsequently served as Chief Scientific Officer, Head of Business Development, Chief Operating Officer and Senior Vice President, Corporate Development, of Proteros, a discovery services company based in Munich and Boston. He co-founded IMD Natural Solutions, developer of the all-natural preservative agent Nagardo®, which was acquired by Lanxess AG in 2017. Peter holds a Master in Chemistry, a PhD from the Max Planck Institute for Biochemistry/TU Munich (Structural Biology, Prof. Dr. Robert Huber), and an MBA.

Mylène Fleurant

Head of Quality

Mylène Fleurant joined Opterion Health in July 2021 as Head of Quality having spent more than 20 years in leading quality (QA) functions in the life sciences industry. She worked for 10 years as Region Head Quality Europe at Novartis and implemented global quality systems at Merck Serono. Prior to founding her own consulting company in 2019, Mylène was Global Head of QA at Novimmune and VP Quality Affairs at Alvotech.

Mylène is a chemical engineer and holds a master’s degree from the University of Sherbrooke, Canada, as well as a degree in Quality Assurance Management from L’Ecole de Technologie Supérieure (ETS) at the University of Quebec.

Daniel Lustenberger

Chief Financial Officer

Daniel Lustenberger is an experienced international finance, accounting and management consulting professional and joined Opterion Health in September 2021 as Chief Financial Officer (CFO). He is a Swiss Certified Public Accountant, holds an Executive MBA from IMD in Lausanne and has 20 years of life sciences and technology experience.

Daniel supports several start-ups and growth companies, particularly in the life sciences and high tech sectors, as a part-time CFO, business advisor and board member.

Prior to Opterion, he held senior finance positions with Vifor Pharma, Gategroup and DKSH. In his early career, he spent several years with PwC, providing advisory services in M&A, IPOs, process and system improvements, corporate governance and risk management.

Jan Anders Karlsson

Board Member
Dr Jan-Anders Karlsson, PhD, has 40 years of experience as a CEO and board member in pharma and biotech companies in Europe, Asia and the US. Jan-Anders was a founder and CEO of Reset Pharmaceuticals Inc, and prior to this served as CEO of Verona Pharma, a NASDAQ-listed biopharmaceutical company developing respiratory drugs. As CEO of S*BIO Pte Ltd, he focused on the discovery and development of drugs for the treatment of cancer – its product Vonjo (pacritinib) is approved in the US. Prior to S*BIO, he was Head of Pharma Global Research at Bayer Healthcare AG and held positions in Rhone-Poulenc Rorer and Astra AB. Jan-Anders received a doctorate in Medical Science (PhD) in Clinical Experimental Pharmacology from the University of Lund, Sweden.

Andreas Schmidt

Board Member

Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.

During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.

In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.

Ricardo Cordero

Vice Chairman
Dr Ricardo Cordero, PhD, serves as Vice Chairman of Opterion Health since 2016. Ricardo has over 30 years of experience in the Financial Services Industry where he held various senior positions, for example as CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, Co-founder and Co-CEO at BWO Bank, etc. Further, he is a passionate and experienced private Swiss investor and holds various investments in the Life Science, Technology and high-end Consumer Goods industry.

David Ebsworth

Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. He has chaired several private and public companies and has served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David is currently Chairman of Verona Pharma and Actimed Therapeutics.

Guido Grentzmann

Founder / CSO
Dr Guido Grenzmann, PhD, is the founder of Opterion Health and has more than 25 years of experience in Pharma R&D and Project Management. After academic work on bacterial and viral mechanisms of translational regulation, he became Group Leader Molecular Biology/Genomics at Pfizer and Director Biochemistry/GeneProfiling at Altana Pharma where he worked in Discovery of inflammation in respiratory diseases. In 2007 he founded PBS PharmaBioServices providing contract research and consulting mainly in inflammatory diseases, in multiple therapeutic domains. 2012, Guido founded Opterion, with the aim to develop a new PD solution, to decrease side-effects of this promising therapy.